openPR Logo
Press release

DUB Inhibitors Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight

09-01-2025 09:05 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

DUB Inhibitors Pipeline 2025: Comprehensive Clinical Trials

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, DUB Inhibitors pipeline constitutes key companies continuously working towards developing DUB Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"DUB Inhibitors Pipeline Insight" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the DUB Inhibitors Market.

The DUB Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the DUB Inhibitors Pipeline Report: https://www.delveinsight.com/sample-request/dub-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel DUB Inhibitors treatment therapies with a considerable amount of success over the years.
• DUB Inhibitors companies working in the treatment market are USP7 Ubiquigent, Carmot Therapeutics, Molecure, Mission Therapeutics, Tango Therapeutics, Mission Therapeutics, KSQ Therapeutics, Cothera Bioscience, Almac Discovery, Carmot Therapeutics, Progenra, Vivolux, and others, are developing therapies for the DUB Inhibitors treatment
• Emerging DUB Inhibitors therapies in the different phases of clinical trials are- Research program, Small molecules, OAT-4828, MTX325, TNG348, MTX652, KSQ-4279, PC-002, USP30 inhibitor program, USP7 inhibitors program, Research programme: deubiquitinating enzyme inhibitors, MuRF1 inhibitors, VLX1570, and others are expected to have a significant impact on the DUB Inhibitors market in the coming years.
• In July 2024, Mission Therapeutics has secured USD 5.2 million in funding from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Parkinson's UK to support the development of its potential disease-modifying Parkinson's therapy, MTX325.
• In July 2024, Molecure has formed a strategic research partnership with Avicenna Biosciences to advance the discovery and development of innovative small-molecule therapies aimed at targeting USP7.

DUB Inhibitors Overview
DUB inhibitors, or deubiquitinase inhibitors, are a class of compounds that target enzymes called deubiquitinases (DUBs). These enzymes are responsible for removing ubiquitin molecules from proteins, a process known as deubiquitination. Ubiquitination and deubiquitination play essential roles in regulating various cellular processes, including protein degradation, DNA repair, signal transduction, and immune response.

Get a Free Sample PDF Report to know more about DUB Inhibitors Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dub-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging DUB Inhibitors Drugs Under Different Phases of Clinical Development Include:
• Research program: USP7 Ubiquigent
• Small molecules: Carmot Therapeutics
• OAT-4828: Molecure
• MTX325: Mission Therapeutics
• TNG348: Tango Therapeutics
• MTX652: Mission Therapeutics
• KSQ-4279: KSQ Therapeutics
• PC-002: Cothera Bioscience
• USP30 inhibitor program: Mission Therapeutics
• USP7 inhibitors program: Almac Discovery
• Research programme: deubiquitinating enzyme inhibitors: Carmot Therapeutics
• MuRF1 inhibitors: Progenra
• VLX1570: Vivolux

DUB Inhibitors Pipeline Therapeutics Assessment
• DUB Inhibitors Assessment by Product Type
• DUB Inhibitors By Stage and Product Type
• DUB Inhibitors Assessment by Route of Administration
• DUB Inhibitors By Stage and Route of Administration
• DUB Inhibitors Assessment by Molecule Type
• DUB Inhibitors by Stage and Molecule Type

DelveInsight's DUB Inhibitors Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further DUB Inhibitors product details are provided in the report. Download the DUB Inhibitors pipeline report to learn more about the emerging DUB Inhibitors therapies
https://www.delveinsight.com/sample-request/dub-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the DUB Inhibitors Therapeutics Market include:
Key companies developing therapies for DUB Inhibitors are - Mission Therapeutics, Ubiquigent, Almac Discovery, KSQ Therapeutics, Carmot Therapeutics, Progenra, Hybrigenics, and others.

DUB Inhibitors Pipeline Analysis:
The DUB Inhibitors pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of DUB Inhibitors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for DUB Inhibitors Treatment.
• DUB Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• DUB Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the DUB Inhibitors market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about DUB Inhibitors drugs and therapies
https://www.delveinsight.com/sample-request/dub-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DUB Inhibitors Pipeline Market Drivers
• Novel candidates for target-directed drug development, DUBs play major roles in diverse cellular-processes are some of the important factors that are fueling the DUB Inhibitors Market.

DUB Inhibitors Pipeline Market Barriers
• However, lack of in-depth studies to understand their natural regulatory mechanisms, inhibitors developed could have severe adverse effects by affecting non-target pathways and other factors are creating obstacles in the DUB Inhibitors Market growth.

Scope of DUB Inhibitors Pipeline Drug Insight
• Coverage: Global
• Key DUB Inhibitors Companies: USP7 Ubiquigent, Carmot Therapeutics, Molecure, Mission Therapeutics, Tango Therapeutics, Mission Therapeutics, KSQ Therapeutics, Cothera Bioscience, Almac Discovery, Carmot Therapeutics, Progenra, Vivolux, and others
• Key DUB Inhibitors Therapies: Research program, Small molecules, OAT-4828, MTX325, TNG348, MTX652, KSQ-4279, PC-002, USP30 inhibitor program, USP7 inhibitors program, Research programme: deubiquitinating enzyme inhibitors, MuRF1 inhibitors, VLX1570, and others
• DUB Inhibitors Therapeutic Assessment: DUB Inhibitors current marketed and DUB Inhibitors emerging therapies
• DUB Inhibitors Market Dynamics: DUB Inhibitors market drivers and DUB Inhibitors market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release DUB Inhibitors Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight here

News-ID: 4165739 • Views:

More Releases from DelveInsight Business Research

Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market. The Spinocerebellar
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics. DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,
Myocardial Infarction Market Positioned for Accelerated Development Through 2034, DelveInsight Finds
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for DUB

DUB Inhibitors Pipeline 2025: Comprehensive Clinical Trials and Therapies Analys …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, DUB Inhibitors pipeline constitutes key companies continuously working towards developing DUB Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "DUB Inhibitors Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/dub-inhibitors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the DUB Inhibitors Market. The DUB Inhibitors Pipeline report embraces in-depth
Dysfunctional Uterine Bleeding Market Overview: Global Size, Share, Analysis, an …
" The Dysfunctional Uterine Bleeding (DUB) market is a significant and growing sector within the healthcare industry, driven by the increasing prevalence of abnormal uterine bleeding among women globally. DUB, characterized by irregular or heavy menstrual bleeding not associated with structural abnormalities of the uterus or systemic disease, affects a substantial portion of the female population, impacting their quality of life and healthcare utilization. Key drivers for growth in this market
DUB Inhibitors Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, DUB Inhibitors pipeline constitutes key companies continuously working towards developing DUB Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "DUB Inhibitors Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the DUB Inhibitors Market. The DUB Inhibitors Pipeline report offers a comprehensive
DUB Inhibitors Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Cli …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, DUB Inhibitors pipeline constitutes key companies continuously working towards developing DUB Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "DUB Inhibitors Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the DUB Inhibitors Market. The DUB Inhibitors Pipeline
business tactics of Global User Experience Industry market by top key vendors li …
ReportsWeb delivers well-researched industry-wide information on the User Experience Industry market. It studies the market’s essential aspects such as top participants, expansion strategies, business models, and other market features to gain improved market insights. Additionally, it focuses on the latest advancements in the sector and technological development, executive tools, and tactics that can enhance the performance of the sectors. To get sample Copy of the report, along with the TOC, Statistics,
Lip Powder Market: Palettes form Reigns Supreme with over 55 Percent Sale; Beaut …
Public concern regarding toxicity looming with cosmetics have become a hot issue. Lip powder has been used to ameliorate lipstick and to exfoliate to get rid of dry flakes as powders augment texture of lips. Lip powder has been the latest evolution in lipstick. Lip powder has been touted as the most notable innovation for a host of beauty brands. These excerpts are according to the report titled, “Lip Powder